Natco Pharma jumps on getting CDSCO’s approval for Semaglutide Injection in India
Natco Pharma is currently trading at Rs. 885.35, up by 63.25 points or 7.69% from its previous closing of Rs. 822.10 on the BSE.
The scrip opened at Rs. 825.05 and has touched a high and low of Rs. 895.00 and Rs. 825.05 respectively. So far 382 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1059.60 on 24-Jul-2025 and a 52 week low of Rs. 660.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 895.00 and Rs. 815.05 respectively. The current market cap of the company is Rs. 14724.62 crore.
The promoters holding in the company stood at 49.48%, while Institutions and Non-Institutions held 20.54% and 29.97% respectively.
Natco Pharma has received approval from Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic Semaglutide Injection in India. NATCO will launch the product in the India market in March 2026. Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.
